CSR Analysis Servier
servier.comDevelopment and marketing of pharmaceuticals in the fields of oncology, cardiometabolism, and neurology.
Development and marketing of pharmaceuticals in the fields of oncology, cardiometabolism, and neurology.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Pierre Fabre
B
Development and marketing of pharmaceutical and dermo-cosmetic products, with a focus on oncology, dermatology, rare diseases, chronic diseases, and family health.
Chiesi SAS
B
Development and marketing of pharmaceuticals in respiratory, neonatology, transplantation, and rare diseases.
AstraZeneca
B
Research and development of pharmaceuticals and biotechnologies for various diseases, including cardiovascular, renal, and metabolic diseases.
Initiatives identified among leaders
Engagement de réduction des émissions GES aligné sur SBTi pour 2030.
“Pierre Fabre a adopté une stratégie climat validée...” - Pierre FabreMesure et publication annuelle des émissions GES Scope 3
“AstraZeneca publie des données détaillées sur ses ...” - AstraZenecaAugmentation de l'utilisation d'énergies renouvelables
“Chiesi SAS a obtenu la certification B Corp en rec...” - Chiesi SAS64% of similar organizations communicate on CSR issues
+2093 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports
